Harnessing the trophic and modulatory potential of statins in a dopaminergic cell line

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Synapse

• Publication date

  2016-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/syn.21881PMID 26695835
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.

  2015cited by this paper
• AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.

  2015cited by this paper
• Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons

  2015cited by this paper
• Multitarget intervention of Fasudil in the neuroprotection of dopaminergic neurons in MPTP-mouse model of Parkinson's disease.

  2015cited by this paper
• The neuroprotective role of vesicular monoamine transporter 2 in neurodegenerative diseases.

  2015cited by this paper
• Inhibiting Geranylgeranylation Increases Neurite Branching and Differentially Activates Cofilin in Cell Bodies and Growth Cones

  2014influential reference
• Statins in neurological disorders: an overview and update.

  2014cited by this paper
• Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo

  2014cited by this paper
• Protective and toxic roles of dopamine in Parkinson's disease

  2014cited by this paper
• Discontinuation of statin therapy associates with Parkinson disease

  2013cited by this paper
• Simvastatin Promotes Adult Hippocampal Neurogenesis by Enhancing Wnt/β-Catenin Signaling

  2013cited by this paper
• Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s disease

  2013cited by this paper
• A role for Sv2c in basal ganglia functions.

  2013cited by this paper
• Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis.

  2013cited by this paper
• Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.

  2013cited by this paper
• Simvastatin Induced Neurite Outgrowth Unveils Role of Cell Surface Cholesterol and Acetyl CoA Carboxylase in SH-SY5Y Cells

  2013influential reference
• Simvastatin Induces Neuroprotection in 6‐OHDA‐Lesioned PC12 via the PI3K/AKT/Caspase 3 Pathway and Anti‐Inflammatory Responses

  2013cited by this paper
• Importance of cholesterol in dopamine transporter function

  2012cited by this paper
• Expanding roles for SREBP in metabolism.

  2012cited by this paper
• Atorvastatin enhances neurite outgrowth in cortical neurons in vitro via up-regulating the Akt/mTOR and Akt/GSK-3β signaling pathways

  2012influential reference
• Isoprenoids and Related Pharmacological Interventions: Potential Application in Alzheimer’s Disease

  2012cited by this paper
• Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms.

  2012cited by this paper
• Prospective study of statin use and risk of Parkinson disease.

  2012cited by this paper
• Role of HMG-CoA Reductase Inhibitors in Neurological Disorders

  2012cited by this paper
• Atorvastatin stimulates neuroblastoma cells to induce neurite outgrowth by increasing cellular prion protein expression.

  2012cited by this paper
• Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3

  2011cited by this paper
• Distribution of SV2C mRNA and protein expression in the mouse brain with a particular emphasis on the basal ganglia system.

  2011cited by this paper
• Prospects of Statins in Parkinson Disease

  2011cited by this paper
• Rac1 Protein Rescues Neurite Retraction Caused by G2019S Leucine-rich Repeat Kinase 2 (LRRK2)*

  2011cited by this paper
• Statins: multiple neuroprotective mechanisms in neurodegenerative diseases.

  2011cited by this paper
• Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice.

  2011cited by this paper
• Simvastatin Prevents Dopaminergic Neurodegeneration in Experimental Parkinsonian Models: The Association with Anti-Inflammatory Responses

  2011cited by this paper
• Regulation of dopamine transporter function by protein‐protein interactions: new discoveries and methodological challenges

  2010cited by this paper
• Clinical progression in Parkinson disease and the neurobiology of axons

  2010cited by this paper
• Rapid neurite outgrowth in neurosecretory cells and neurons is sustained by the exocytosis of a cytoplasmic organelle, the enlargeosome

  2010influential reference
• Diabetes and insulin in regulation of brain cholesterol metabolism.

  2010cited by this paper
• Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies.

  2010cited by this paper
• Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies.

  2010cited by this paper
• Protective Actions of the Vesicular Monoamine Transporter 2 (VMAT2) in Monoaminergic Neurons

  2009cited by this paper
• Simvastatin Inhibits the Activation of p21ras and Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson's Disease

  2009cited by this paper
• Statins: mechanisms of neuroprotection.

  2009cited by this paper
• Physical and Functional Interaction between the Dopamine Transporter and the Synaptic Vesicle Protein Synaptogyrin-3

  2009cited by this paper
• Mevastatin‐induced neurite outgrowth of neuroblastoma cells via activation of EGFR

  2009influential reference
• Liver X receptors and oxysterols promote ventral midbrain neurogenesis in vivo and in human embryonic stem cells.

  2009cited by this paper
• Statin use and the risk of Parkinson disease

  2008cited by this paper
• VMAT2 and dopamine neuron loss in a primate model of Parkinson’s disease

  2008cited by this paper
• Phorbol ester induced trafficking‐independent regulation and enhanced phosphorylation of the dopamine transporter associated with membrane rafts and cholesterol

  2008cited by this paper
• Statins reduce neuronal α‐synuclein aggregation in in vitro models of Parkinson’s disease

  2008cited by this paper
• Analyzing real-time PCR data by the comparative CT method

  2008cited by this paper
• The Liver X Receptor (LXR) and Hepatic Lipogenesis

  2007cited by this paper
• SREBP-1 regulates the expression of heme oxygenase 1 and the phosphatidylinositol-3 kinase regulatory subunit p55γ Published, JLR Papers in Press, April 23, 2007.

  2007cited by this paper
• Neuronal differentiation and long-term culture of the human neuroblastoma line SH-SY5Y.

  2007cited by this paper
• Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease

  2007cited by this paper
• Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells.

  2007cited by this paper
• Statins Increase Neurogenesis in the Dentate Gyrus, Reduce Delayed Neuronal Death in the Hippocampal CA3 Region, and Improve Spatial Learning in Rat after Traumatic Brain Injury

  2007cited by this paper
• Δ5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARα, in THP-1 cells

  2007cited by this paper
• THE LIVER X RECEPTOR AND HEPATIC LIPOGENESIS: THE CARBOHYDRATE-RESPONSE ELEMENT BINDING PROTEIN IS A TARGET GENE OF LXR

  2006cited by this paper
• The 3‐hydroxy‐3‐methylglutaryl co‐enzyme A reductase inhibitor pravastatin enhances neurite outgrowth in hippocampal neurons

  2006cited by this paper
• Synaptophysin enhances the neuroprotection of VMAT2 in MPP+-induced toxicity in MN9D cells.

  2005cited by this paper
• Axon degeneration mechanisms: commonality amid diversity

  2005cited by this paper
• Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver.

  2004cited by this paper
• HMG‐CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis

  2004influential reference
• Presymptomatic compensation in Parkinson's disease is not dopamine-mediated.

  2003cited by this paper
• Role of Dopamine Transporter Against MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) Neurotoxicity in Mice

  2003cited by this paper
• Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein.

  2002cited by this paper
• Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein

  2002cited by this paper
• High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production

  2002cited by this paper
• Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata.

  2000influential reference
• Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle

  1999cited by this paper
• Sterol Regulatory Element-binding Protein-1 as a Key Transcription Factor for Nutritional Induction of Lipogenic Enzyme Genes*

  1999cited by this paper
• The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter.

  1998cited by this paper
• Increased MPTP Neurotoxicity in Vesicular Monoamine Transporter 2 Heterozygote Knockout Mice

  1998cited by this paper
• Uptake and Release of Neurotransmitters

  1998cited by this paper
• Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach.

  1998cited by this paper
• VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity.

  1997cited by this paper
• ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism.

  1996cited by this paper
• Simvastatin inhibits the division and induces neurite-like outgrowth in PC12 cells.

  1996cited by this paper
• Trace: Tennessee Research and Creative Exchange Nutrition Publications and Other Works Nutrition Central Role for Liver X Receptor in Insulin-mediated Activation of Srebp-1c Transcription and Stimulation of Fatty Acid Synthesis in Liver. Recommended Citation

  year unknowncited by this paper

• The Search for Disease Modification in Parkinson’s Disease—A Review of the Literature

  2025cites this paper
• The effects of cholesterol and statins on Parkinson’s neuropathology: a narrative review

  2024cites this paper
• Pros and cons for statins use and risk of Parkinson's disease: An updated perspective

  2023cites this paper
• Association of cholesterol level with dopamine loss and motor deficits in Parkinson disease: A cross‐sectional study

  2022cites this paper
• Microarray profiling of hypothalamic gene expression changes in Huntington’s disease mouse models

  2022cites this paper
• Effects of statins on dopamine loss and prognosis in Parkinson's disease.

  2021cites this paper
• Knowledge graph analytics platform with LINCS and IDG for Parkinson's disease target illumination

  2021cites this paper
• Lipid Analysis of the 6-Hydroxydopamine-Treated SH-SY5Y Cell Model for Parkinson’s Disease

  2019cites this paper
• The synaptic vesicle glycoprotein 2: structure, function, and disease relevance.

  2019cites this paper
• Atorvastatin Prevents Early Oxidative Events and Modulates Inflammatory Mediators in the Striatum Following Intranasal 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Administration in Rats

  2018cites this paper
• U18666A, an activator of sterol regulatory element binding protein pathway, modulates presynaptic dopaminergic phenotype of SH‐SY5Y neuroblastoma cells

  2017cites this paper
• Synaptic vesicle 2C and its synaptic-related function.

  2017cites this paper
• Succinate dehydrogenase in Parkinson’s disease

  2017cites this paper
• Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson’s Disease: Rationale for Clinical Trial, and Current Progress

  2017cites this paper
• Modulation of the expression and function of dopaminergic presynaptic proteins by the statins : Potential implication for the therapeutic intervention in Parkinson’s disease.

  2015cites this paper